• Publications
  • Influence
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
TLDR
The FACT-G meets or exceeds all requirements for use in oncology clinical trials, including ease of administration, brevity, reliability, validity, and responsiveness to clinical change. Expand
Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes.
TLDR
It is recommended that the MID is based primarily on relevant patient-based and clinical anchors, with clinical trial experience used to further inform understanding of MID. Expand
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
TLDR
The FACT-B is appropriate for use in oncology clinical trials, as well as in clinical practice, and demonstrates ease of administration, brevity, reliability, validity, and sensitivity to change. Expand
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.
TLDR
Systematically collecting and reporting the recommended information needed to evaluate the clinical importance of treatment outcomes of Chronic pain clinical trials will allow additional validation of proposed benchmarks and provide more meaningful comparisons of chronic pain treatments. Expand
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
TLDR
Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with pac litaxel alone. Expand
Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy—spiritual well-being scale (FACIT-Sp)
TLDR
Results of the two studies demonstrate that the FACIT-Sp is a psychometrically sound measure of spiritual well-being for people with cancer and other chronic illnesses. Expand
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008.
TLDR
The first large-scale testing of PROMIS item banks and their short forms provide evidence that they are reliable and precise measures of generic symptoms and functional reports comparable to legacy instruments. Expand
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
TLDR
Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy. Expand
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
TLDR
Axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma and resulted in significantly longer progression-free survival (PFS) compared with sorafenib. Expand
Psychometric Evaluation and Calibration of Health-Related Quality of Life Item Banks: Plans for the Patient-Reported Outcomes Measurement Information System (PROMIS)
TLDR
An overview of the methods used in the PROMIS item analyses and proposed calibration of item banks is provided and recommendations are provided for future evaluations of item Banks in HRQOL assessment. Expand
...
1
2
3
4
5
...